BCTX - BriaCell Therapeutics Corp

3.73
-0.180   -4.826%

Share volume: 275,999
Last Updated: 04-23-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$3.91
-0.18
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
53%
Profitability 35%
Dept financing 38%
Liquidity 50%
Performance 75%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-7.21%
1 Month
-9.02%
3 Months
-19.44%
6 Months
-72.95%
1 Year
-38.14%
2 Year
70.32%
Key data
Stock price
$3.73
P/E Ratio 
0.00
DAY RANGE
$3.71 - $3.97
EPS 
-$27.44
52 WEEK RANGE
$0.61 - $14.68
52 WEEK CHANGE
-$28.27
MARKET CAP 
20.723 M
YIELD 
N/A
SHARES OUTSTANDING 
1.884 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
01-29-2025
NEXT EARNINGS DATE
06-13-2025
BETA 
1.98
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$217,969
AVERAGE 30 VOLUME 
$171,385
Company detail
CEO: William V. Williams
Region: US
Website: briacell.com
Employees: 8
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

BriaCell Therapeutics Corp. engages in developing immunotherapies for the treatment of cancer. Lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors. Company also has a cooperative research and development agreement with the National Cancer Institute.

Recent news